Loading
Life sciences · Phase 2/3 Trial
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2/3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07149649). This is a study registration, not published results. Lead sponsor: Swiss Cancer Institute. Recruitment status: RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 230 participants (ESTIMATED). Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer. Interventions: DRUG: Magnesiocard; DRUG: Magnesium Diasporal; OTHER: Microcrystalline cellulose; OTHER: Isotonic saline solution 0.9%. Primary outcome measures: Primary endpoint of Phase II part: Progression-free survival (PFS) , From randomization to PD or death, up to 10 years; Primary endpoint of Phase III part: Overall survival (OS) , From randomization to PD or death, up to 10 years. Brief summary: This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.